Letter in Reply to Xu

We appreciate the interest and comments by Xu for our article, which studied the incidence of pneumonitis EGFR tyrosine kinase inhibitors (EGFR-TKI) in non-small-cell lung cancer (NSCLC) patients treated in clinical trials [1].

Source: Lung Cancer - November 8, 2018 Category: Cancer & Oncology Authors: Chong Hyun Suh, Kyung Won Kim, Mizuki Nishino Source Type: research